Gene Therapy Used in Cancer Treatment
Tóm tắt
Cancer has been, from the beginning, a target of intense research for gene therapy approaches. Currently, more than 60% of all on-going clinical gene therapy trials worldwide are targeting cancer. Indeed, there is a clear unmet medical need for novel therapies. This is further urged by the fact that current conventional cancer therapies are frequently troubled by their toxicities. Different gene therapy strategies have been employed for cancer, such as pro-drug activating suicide gene therapy, anti-angiogenic gene therapy, oncolytic virotherapy, gene therapy-based immune modulation, correction/compensation of gene defects, genetic manipulation of apoptotic and tumor invasion pathways, antisense, and RNAi strategies. Cancer types, which have been targeted with gene therapy, include brain, lung, breast, pancreatic, liver, colorectal, prostate, bladder, head and neck, skin, ovarian, and renal cancer. Currently, two cancer gene therapy products have received market approval, both of which are in China. In addition, the stimulation of the host’s immune system, using gene therapeutic approaches, has gained vast interest. The intention of this review is to point out the most commonly viral and non-viral vectors and methods used in cancer gene therapy, as well as highlight some key results achieved in clinical trials.
Từ khóa
Tài liệu tham khảo
Bissell, 2011, Why donʼt we get more cancer? A proposed role of the microenvironment in restraining cancer progression, Nat. Med., 17, 320, 10.1038/nm.2328
Rogers, 1968, Use of viruses as carriers of added genetic information, Nature, 219, 749, 10.1038/219749a0
Rogers, 1973, Induction of arginase activity with the Shope papilloma virus in tissue culture cells from an argininemic patient, J. Exp. Med., 137, 1091, 10.1084/jem.137.4.1091
Terheggen, 1975, Unsuccessful trial of gene replacement in arginase deficiency, Z. Kinderheilkd., 119, 1
Rosenberg, 1990, Gene transfer into humans—Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction, N. Engl. J. Med., 323, 570, 10.1056/NEJM199008303230904
MacMillan, 1982, The Cline affair, Nurs. Times, 78, 383
Coughlan, 2010, Tropism-modification strategies for targeted gene delivery using adenoviral vectors, Viruses, 2, 2290, 10.3390/v2102290
Biffi, 2011, Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection, Blood, 117, 5332, 10.1182/blood-2010-09-306761
Matrai, 2010, Recent advances in lentiviral vector development and applications, Mol. Ther., 18, 477, 10.1038/mt.2009.319
Sharma, 2009, Adenovirus receptors and their implications in gene delivery, Virus Res., 143, 184, 10.1016/j.virusres.2009.02.010
Heyde, 2007, Gene therapy used for tissue engineering applications, J. Pharm. Pharmacol., 59, 329, 10.1211/jpp.59.3.0002
Pathak, 2009, Recent trends in non-viral vector-mediated gene delivery, Biotechnol. J., 4, 1559, 10.1002/biot.200900161
Mudhakir, 2009, Learning from the viral journey: How to enter cells and how to overcome intracellular barriers to reach the nucleus, AAPS J., 11, 65, 10.1208/s12248-009-9080-9
Escoffre, 2010, Gene transfer: How can the biological barriers be overcome?, J. Membr. Biol., 236, 61, 10.1007/s00232-010-9275-0
Lang, 2003, Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results, J. Clin. Oncol., 21, 2508, 10.1200/JCO.2003.21.13.2508
Raty, 2008, Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications, Curr. Mol. Pharmacol., 1, 13, 10.2174/1874467210801010013
Han, 2003, Effectiveness of recombinant adenovirus p53 injection on laryngeal cancer: Phase I clinical trial and follow up, Zhonghua Yi Xue Za Zhi, 83, 2029
Peng, 2005, Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers, Hum. Gene Ther., 16, 1016, 10.1089/hum.2005.16.1016
Bischoff, 1996, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells, Science, 274, 373, 10.1126/science.274.5286.373
Chiocca, 2004, A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting, Mol. Ther., 10, 958, 10.1016/j.ymthe.2004.07.021
Yu, 2007, Clinical trials with oncolytic adenovirus in China, Curr. Cancer. Drug Targets, 7, 141, 10.2174/156800907780058817
Hu, 2006, A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor, Clin. Cancer Res., 12, 6737, 10.1158/1078-0432.CCR-06-0759
Harrington, 2010, Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck, Clin. Cancer Res., 16, 4005, 10.1158/1078-0432.CCR-10-0196
Kershaw, 2013, Gene-engineered T cells for cancer therapy, Nat. Rev. Cancer, 13, 525, 10.1038/nrc3565
Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003
Robbins, 2011, Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1, J. Clin. Oncol., 29, 917, 10.1200/JCO.2010.32.2537
Kochenderfer, 2013, Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors, Nat. Rev. Clin. Oncol., 10, 267, 10.1038/nrclinonc.2013.46
Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388
Herman, 2013, Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: Final results, J. Clin. Oncol., 31, 886, 10.1200/JCO.2012.44.7516
Malmstrom, 2010, AdCD40L immunogene therapy for bladder carcinoma—The first phase I/IIa trial, Clin. Cancer Res., 16, 3279, 10.1158/1078-0432.CCR-10-0385
Chiocca, 2008, A phase I trial of Ad.hIFN-beta gene therapy for glioma, Mol. Ther., 16, 618, 10.1038/sj.mt.6300396
Freeman, 1993, The “bystander effect”: Tumor regression when a fraction of the tumor mass is genetically modified, Cancer Res., 53, 5274
Sandmair, 2000, Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses, Hum. Gene Ther., 11, 2197, 10.1089/104303400750035726
Eck, 1996, Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial, Hum. Gene Ther., 7, 1465, 10.1089/hum.1996.7.12-1465
Rainov, 2000, A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme, Hum. Gene Ther., 11, 2389, 10.1089/104303400750038499
Immonen, 2004, AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study, Mol. Ther., 10, 967, 10.1016/j.ymthe.2004.08.002
Westphal, M., Yla-Herttuala, S., Martin, J.F., Warnke, P., Menei, P., Eckland, D., Kinley, J., Kay, R., and Ram, Z. (2013). Adenovirus-mediated gene therapy with stimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomised, open-label, phase 3 trial. Lancet Oncol., in press.
Thoma, 2013, Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: Implications for ovarian cancer therapy, Virology, 447, 74, 10.1016/j.virol.2013.08.032
Wirth, 2006, Safety profile of plasmid/liposomes and virus vectors in clinical gene therapy, Curr. Drug Saf., 1, 253, 10.2174/157488606777934440
Wang, 2011, The next step in gene delivery: Molecular engineering of adeno-associated virus serotypes, J. Mol. Cell. Cardiol., 50, 793, 10.1016/j.yjmcc.2010.10.017
Kim, 2011, A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: The safety profile of ad5/3-Delta24 in advance of a phase I clinical trial in ovarian cancer patients, Hum. Gene Ther., 22, 821, 10.1089/hum.2010.180
Wang, 2011, Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors, Hum. Gene Ther., 22, 1389, 10.1089/hum.2011.031
Barnett, 2002, Targeted adenoviral vectors, Biochim. Biophys. Acta, 1575, 1, 10.1016/S0167-4781(02)00249-X
Cronin, 2005, Altering the tropism of lentiviral vectors through pseudotyping, Curr. Gene Ther., 5, 387, 10.2174/1566523054546224
Kim, 2009, Hypoxia-specific gene expression for ischemic disease gene therapy, Adv. Drug Deliv. Rev., 61, 614, 10.1016/j.addr.2009.04.009
Harvey, 2011, Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo, Cancer Gene Ther., 18, 773, 10.1038/cgt.2011.43
Urnov, 2010, Genome editing with engineered zinc finger nucleases, Nat. Rev. Genet., 11, 636, 10.1038/nrg2842
Staunstrup, 2009, Hybrid lentivirus-transposon vectors with a random integration profile in human cells, Mol. Ther., 17, 1205, 10.1038/mt.2009.10
Mates, 2009, Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates, Nat. Genet., 41, 753, 10.1038/ng.343
VandenDriessche, 2009, Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells, Blood, 114, 1461, 10.1182/blood-2009-04-210427
Patel, 2000, Radiation-induced sarcoma, Curr. Treat. Options Oncol., 1, 258, 10.1007/s11864-000-0037-6
Harris, 1976, The carcinogenicity of anticancer drugs: A hazard in man, Cancer, 37, 1014, 10.1002/1097-0142(197602)37:2+<1014::AID-CNCR2820370805>3.0.CO;2-Z
Boffetta, 1994, Secondary malignancies following cancer chemotherapy, Acta Oncol., 33, 591, 10.3109/02841869409121767